Ono's BMS-partnered EP4 antagonist improves progression-free survival in phase 2 gastric cancer test
Ono Pharmaceutical’s EP4 antagonist hit the primary progression-free survival endpoint in a phase 2 trial in patients with gastric cancer. The biopharma evaluated the Bristol Myers Squibb-partnered ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback